Literature DB >> 18241716

Papillary thyroid cancer: pathological parameters as prognostic factors in different classes of age.

Paolo Miccoli1, Michele N Minuto, Clara Ugolini, Erica Panicucci, Marco Massi, Piero Berti, Fulvio Basolo.   

Abstract

OBJECTIVE: To analyze aspects of a series of papillary thyroid carcinomas and evaluate the prognostic features specific to different age classes. STUDY
DESIGN: Retrospective study. SUBJECTS AND METHODS: From 2000 to 2005, 2709 patients underwent a total thyroidectomy for papillary thyroid carcinoma in our department. Patients were divided into three groups: <18 years (G1), 19 to 45 years (G2), and >46 years (G3). Histologic and clinical features were statistically evaluated.
RESULTS: Tumor size was larger in G1 when compared with both G2 and G3 (P < 0.0001). Infiltration of the thyroid capsule and node metastases were higher in G1 than both G2 and G3 (P < 0.0001). The Tall-cell variant was more represented in G2 and G3.
CONCLUSION: In the pediatric population, papillary carcinoma is a more aggressive disease. Because pediatric cancers have a better prognosis than their adult counterparts, this does not influence patient outcome. Age can then be considered the most important factor in determining prognosis.

Entities:  

Mesh:

Year:  2008        PMID: 18241716     DOI: 10.1016/j.otohns.2007.10.034

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  10 in total

1.  Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population.

Authors:  Ryan J Gertz; Yuri Nikiforov; William Rehrauer; Lee McDaniel; Ricardo V Lloyd
Journal:  Arch Pathol Lab Med       Date:  2016-02       Impact factor: 5.534

2.  Features of papillary thyroid carcinoma in patients older than 75 years.

Authors:  Antonio Toniato; Chiara Bernardi; Andrea Piotto; Domenico Rubello; Maria Rosa Pelizzo
Journal:  Updates Surg       Date:  2011-03-17

3.  Expression of MMP-1 in invasive well-differentiated thyroid carcinoma.

Authors:  Aviram Mizrachi; Rumelia Koren; Tuvia Hadar; Eitan Yaniv; Sara Morgenstern; Jacob Shvero
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-21       Impact factor: 2.503

4.  Clinical and molecular features of papillary thyroid cancer in adolescents and young adults.

Authors:  Menno R Vriens; Willieford Moses; Julie Weng; Miao Peng; Ann Griffin; Archie Bleyer; Brad H Pollock; Daniel J Indelicato; Jimmy Hwang; Electron Kebebew
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

5.  Age-based disparities in the use of total thyroidectomy for papillary thyroid carcinoma.

Authors:  I V Shevchyk; B A Cobian; S R Martinez
Journal:  Clin Transl Oncol       Date:  2017-04-24       Impact factor: 3.405

6.  Prognostic values of thyroid tumours.

Authors:  Suzana Manxhuka-Kerliu; Emine Devolli-Disha; Arsim Gerxhaliu; Halil Ahmetaj; Arijeta Baruti; Sadushe Loxha; Hajdin Thaqi
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

7.  Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension.

Authors:  Megan R Haymart; Simone L Glinberg; Jing Liu; Rebecca S Sippel; Juan C Jaume; Herbert Chen
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-03       Impact factor: 3.478

8.  Age and prognosis of papillary thyroid carcinoma: retrospective stratification into three groups.

Authors:  Jin Seong Cho; Jung Han Yoon; Min Ho Park; Sun Hyoung Shin; Young Jong Jegal; Ji Shin Lee; Hee Kyung Kim
Journal:  J Korean Surg Soc       Date:  2012-10-29

9.  Thyroid Carcinoma Pattern Presentation According to Age.

Authors:  Fábio Muradás Girardi
Journal:  Int Arch Otorhinolaryngol       Date:  2016-07-12

10.  Young age increases the risk of lymph node positivity in papillary thyroid cancer patients: a SEER data-based study.

Authors:  Jing Wang; Jianjun Liu; Huayuan Pan; Chenghao Jiang; Song Liu; Zhengzhi Zhu; Jing Fang; Xucai Zheng; Shikai Hong; Shengying Wang
Journal:  Cancer Manag Res       Date:  2018-09-25       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.